The Goldman Sachs Group Increases Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $200.00

Ascendis Pharma A/S (NASDAQ:ASND) had its target price raised by equities researchers at The Goldman Sachs Group from $180.00 to $200.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price target suggests a potential upside of 40.23% from the company’s current price.

A number of other equities research analysts also recently weighed in on the stock. Stifel Nicolaus started coverage on shares of Ascendis Pharma A/S in a research note on Friday, May 31st. They issued a “buy” rating and a $200.00 target price on the stock. JPMorgan Chase & Co. dropped their price target on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 4th. Oppenheimer reiterated an “outperform” rating and issued a $190.00 price target (up previously from $180.00) on shares of Ascendis Pharma A/S in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research report on Monday. Finally, StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, September 5th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $189.62.

Ascendis Pharma A/S Price Performance

Shares of ASND stock traded up $3.05 on Tuesday, hitting $142.62. The stock had a trading volume of 402,474 shares, compared to its average volume of 426,808. The business has a 50 day moving average of $132.51 and a 200 day moving average of $136.47. The stock has a market cap of $8.30 billion, a price-to-earnings ratio of -14.91 and a beta of 0.63. Ascendis Pharma A/S has a 12-month low of $85.29 and a 12-month high of $161.00.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors and hedge funds have recently modified their holdings of the stock. Gilbert & Cook Inc. raised its holdings in shares of Ascendis Pharma A/S by 8.4% during the fourth quarter. Gilbert & Cook Inc. now owns 2,838 shares of the biotechnology company’s stock worth $357,000 after acquiring an additional 220 shares in the last quarter. Quadrant Capital Group LLC grew its position in shares of Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Ascendis Pharma A/S by 1.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 16,384 shares of the biotechnology company’s stock valued at $2,064,000 after purchasing an additional 159 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at about $1,243,000. Finally, EverSource Wealth Advisors LLC grew its position in Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after buying an additional 91 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.